Our Pricing

Understanding Saxenda and Wegovy Monthly Costs in the UK

When evaluating saxenda vs wegovy monthly cost uk options, understanding both price and clinical efficacy helps you make an informed choice. At Cured Pharmacy, Saxenda starts from £79.00 and Wegovy from £79.00 with transparent pricing before your free consultation. Both are prescription-only GLP-1 receptor agonist injections licensed by the MHRA for weight management, but they differ in dosing frequency, mechanism, and cost structure.

Saxenda vs Wegovy Monthly Cost UK: Price Breakdown

Saxenda (liraglutide) is a daily injection starting from £79.00 at Cured Pharmacy, making it one of the more accessible GLP-1 treatments for UK patients. Each pen contains 18mg of liraglutide delivered over multiple days, requiring daily administration at the same time each day [1].

Wegovy (semaglutide) is a once-weekly injection priced from £79.00 at Cured Pharmacy. The reduced injection frequency appeals to patients seeking convenience, though the monthly cost may vary depending on your prescribed maintenance dose [2]. Both treatments require gradual dose escalation over several weeks to minimise gastrointestinal side effects.

Your final monthly cost depends on the dose your UK prescriber determines is clinically appropriate based on your BMI, medical history, and treatment response. All prescription weight loss medications at Cured Pharmacy require a clinical assessment by a UK-registered prescriber before dispensing.

How Saxenda and Wegovy Work Differently

Saxenda contains liraglutide, a GLP-1 receptor agonist that mimics the glucagon-like peptide-1 hormone naturally produced in your gut. It slows gastric emptying, reduces appetite, and helps regulate blood sugar levels. In the SCALE clinical trial programme, patients achieved an average weight loss of 8% of initial body weight over 56 weeks when combined with lifestyle modifications [1].

Wegovy contains semaglutide, a longer-acting GLP-1 analogue with a half-life of approximately one week, allowing once-weekly dosing. The STEP clinical trials demonstrated that patients on the 2.4mg maintenance dose achieved an average weight reduction of 14.9% over 68 weeks — nearly double the results seen with liraglutide-based treatments [2][3].

Both medications work by reducing hunger signals to the brain, slowing how quickly food leaves your stomach, and improving insulin secretion. The key difference lies in semaglutide's enhanced binding affinity to GLP-1 receptors and extended duration of action, which may explain its superior weight loss outcomes in head-to-head comparisons [3].

Mechanism of Action: Daily vs Weekly Dosing

Saxenda's daily injection schedule maintains steady liraglutide levels throughout each 24-hour period, requiring consistent administration timing for optimal efficacy. Wegovy's weekly injection provides sustained semaglutide exposure across seven days, reducing the burden of daily medication routines. Your UK prescriber will consider your lifestyle, adherence patterns, and clinical goals when recommending the most suitable option.

Clinical Efficacy: Which Treatment Delivers Better Results?

Direct comparison studies show semaglutide consistently outperforms liraglutide in weight reduction outcomes. In the STEP 8 trial, which directly compared once-weekly semaglutide 2.4mg against daily liraglutide 3.0mg, semaglutide produced significantly greater weight loss at 68 weeks (15.8% vs 6.4% average reduction) [3].

However, clinical efficacy extends beyond weight loss percentages. Saxenda may suit patients who prefer gradual dose titration with a well-established safety profile spanning over a decade of clinical use. Wegovy's newer market entry means long-term safety data beyond five years remains limited, though current evidence shows both medications share similar side effect profiles [1][2].

Both treatments demonstrated cardiovascular benefits in their respective trials. The SELECT trial showed semaglutide reduced major adverse cardiovascular events by 20% in patients with established cardiovascular disease, whilst liraglutide showed similar protective effects in the LEADER trial [4][5]. Your prescriber will weigh these factors alongside cost when determining the most appropriate treatment for your individual circumstances.

Real-World Effectiveness vs Clinical Trial Data

Clinical trial results represent ideal conditions with high adherence and regular monitoring. Real-world UK data suggests average weight loss may be lower, typically ranging from 5-10% for Saxenda and 10-15% for Wegovy when used alongside dietary modifications and increased physical activity. Discontinuation rates due to gastrointestinal side effects remain similar between both treatments, affecting approximately 5-10% of patients in the first three months [3].

Saxenda vs Wegovy Monthly Cost UK: Value for Money Analysis

When comparing value, consider both upfront cost and weight loss efficacy per pound spent. Wegovy's higher monthly price delivers approximately double the average weight reduction seen with Saxenda in clinical trials, potentially offering better cost-effectiveness for patients seeking maximum weight loss [3].

Saxenda's lower entry price makes it more accessible for patients with tighter budgets or those wanting to trial GLP-1 therapy before committing to higher-cost options. The daily injection requirement means you'll use the medication consistently, whereas weekly injections may feel more manageable long-term for patients with busy schedules.

At Cured Pharmacy, transparent pricing before consultation allows you to compare costs upfront. Both treatments are available at competitive rates compared to typical market pricing, with no hidden fees or subscription requirements. Your UK prescriber will discuss which option offers the best balance of clinical benefit and affordability based on your weight loss goals and financial considerations.

Side Effects and Safety Considerations

Both Saxenda and Wegovy share similar side effect profiles, with gastrointestinal symptoms being most common. Nausea, diarrhoea, constipation, and vomiting typically occur during dose escalation and often resolve within 4-8 weeks as your body adjusts [1][2]. Taking the injection with food and staying well-hydrated can help minimise these effects.

Serious but rare side effects include pancreatitis, gallbladder disease, and thyroid C-cell tumours (observed in rodent studies but not conclusively demonstrated in humans). Both medications carry a boxed warning regarding thyroid tumours and are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1][2].

Your UK prescriber will review your complete medical history during the online consultation to ensure either treatment is safe and appropriate. Patients with a history of severe gastrointestinal disease, diabetic retinopathy, or renal impairment require careful assessment before starting GLP-1 therapy. All prescription weight loss treatments at Cured Pharmacy include ongoing clinical support from our UK-registered pharmacy team.

Managing Side Effects During Treatment

Most patients tolerate GLP-1 injections well when dose escalation follows the licensed schedule. Starting at lower doses and increasing gradually every 4 weeks allows your digestive system to adapt. If you experience persistent nausea, your prescriber may recommend slowing the titration schedule or remaining at your current dose for an additional month before increasing. Never adjust your dose without consulting your UK prescriber first.

Choosing Between Saxenda and Wegovy: Clinical Guidance

Your UK prescriber considers multiple factors when recommending between Saxenda and Wegovy, including your BMI, weight loss goals, previous treatment responses, medical history, and budget constraints. Patients seeking maximum weight reduction with once-weekly convenience may benefit more from Wegovy, whilst those preferring lower upfront costs and established long-term safety data may find Saxenda more suitable [3].

Both treatments require commitment to lifestyle modifications including reduced calorie intake and increased physical activity. Clinical trials demonstrating their efficacy included structured diet and exercise programmes alongside medication [1][2]. GLP-1 injections are tools to support weight management, not standalone solutions.

At Cured Pharmacy, your free online consultation takes under three minutes and connects you with UK-registered prescribers who specialise in weight management. Superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all clinical services, ensuring every patient receives personalised treatment recommendations based on current NICE and MHRA guidance. If prescribed, your medication ships in discreet packaging with clear administration instructions and ongoing support from our clinical team.

When to Consider Alternative Treatments

If cost remains a barrier, consider Orlistat (from £79.00) or Mysimba (from £79.00) as non-injection alternatives licensed for weight management in the UK. For patients requiring more potent weight reduction, Mounjaro (tirzepatide) offers superior efficacy to both Saxenda and Wegovy, with clinical trials showing average weight loss up to 22.5% [6]. Your prescriber will discuss all suitable options during your consultation, ensuring you receive the most appropriate treatment for your individual circumstances and budget.

Scientific References

1. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Rubino, D. M., Greenway, F. L., Khalid, U., et al. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA, 327(2), 138–150. https://doi.org/10.1001/jama.2021.23619
4. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563
5. Marso, S. P., Daniels, G. H., Brown-Frandsen, K., et al. (2016). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 375(4), 311–322. https://doi.org/10.1056/NEJMoa1603827
6. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment and lifestyle modifications.